Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
--------------------------------------------------------------------
Source: CNBC
Published: 2026-09-21 18:23 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Economy & Finance, Financial Markets, Drugs, Business & Economy
--------------------------------------------------------------------
Snippet:
Novo shares fell as much as 7% on Monday after the company laid out new growth ambitions to revive its fortunes in the booming obesity drug market.
--------------------------------------------------------------------